Case study

Updating the audit process to include the Rx-360 protocol

The context

For several years, Saint-Gobain Life Sciences has been a member of Rx-360 - an international pharmaceutical supply chain consortium designed to protect patient safety through best practice in healthcare supply chains. As part of this, Saint-Gobain Life Sciences has used the Rx-360 Joint Audit Program® for auditing its suppliers. Having experienced the value of Rx-360 and its audit program, Saint-Gobain Life Sciences decided to take part as a supplier in a collaborative cross-industry project, between BioPhorum and Rx-360, aimed at further supporting the scope and focus of audits for Single Use Systems component suppliers. This includes creating a Single Use Audit Guide, and driving adoption by the biomanufacturer community, at a time of unique market pressure. The company volunteered to take part in a BioPhorum/Rx-360 pilot program to demonstrate the utility of a joint audit approach. Together, members trialled the joint audit approach across eight supplier member sites over 14 months and updated the Single Use Audit Guide content. The Phorum also shared ‘lessons learned’ and delivered a Pilot Program summary report on the utility of a Joint Audit Approach, as well as a suite of communications materials.
biophorum external collaborations stgobain resized merck 01 52
Saint-Gobain Life Sciences is a critical supplier in the manufacturing pathway for the global biopharmaceutical industry. The business unit comprises several brands which deliver key components for ensuring regulatory compliance, as well as peak performance, quality, security, and consistency of materials. Products include single use systems for containment, fluid transfer, filtration, connections and flow control, closure systems and single use assemblies.

The story

Saint-Gobain Life Sciences had used Rx-360 among its own suppliers, but not within its own customer base.

The company enabled this by updating its audit process to include the Rx-360 protocol, as updated by the BioPhorum/Rx-360, as part of development of the Pilot Program.

This joint audit approach was so successful, it is now being rolled out more widely across the business, to support rapid expansion. Key benefits included the ability to licence audit reports – which reduced the burden of audits, resulting in impressive efficiencies. The company also gained increased confidence in the quality of audits – which are tailored to SUS use in the biopharmaceutical sector – and delivered in an efficient manner.

Saint-Gobain Life Sciences’ interest peaked when the company needed to relocate one of its sites in Florida, to accommodate additional lines required for significant growth. This change in address notified to customers, triggered a requirement from them for fresh site audits, and within three months, around 50 companies needed an audit of their new facility.

Leaders knew that they did not have capacity to process 50 additional audits at pace, while managing their own rapid business expansion.

They knew the Rx-360 audit would:

 

    • Enable customers to licence a high-quality audit of their new facility – better than many could perform for themselves
    • Respect legal and commercial sensitivities – Some customers are both suppliers and competitors to Saint-Gobain. The system enables completion of valid audit reports, while maintaining organizations’ confidentiality and respecting commercial sensitivities
    • Reduce the need for on-site visits – Freeing up the time of Saint-Gobain senior leadership and subject matter experts for redeployment onto other projects
    • Better meet the specific needs of the biopharmaceutical industry – with a specific SUS Audit Guide approach
    • Accelerate product availability – By allowing more customers to include Saint-Gobain as an approved supplier off the back of the licenced audit report. This helps Saint-Gobain to alleviate supply chain stress for products and enables their release from the new facility.
We found that Rx-360 has a much more comprehensive audit then we would be able to provide to our customers… and also better than most audits that our customers would come in and do.

Polly Hanff, Global Regulatory Affairs and Quality Director

The benefits

Saint-Gobain Healthcare and Life Sciences realized a host of benefits from implementing the updated audit approach, including:

 

    • Reduced burden of administration and site visits – So far, the company has agreed to licence the audit report for its new site 20 times. Estimates suggest the method saved 40 days of Quality personnel’s time, as well as further hours from the Senior Leadership Team and SMEs supporting on-site audits.
    • Redeploying staff effort – That time, coupled with hours spent on preparation and follow-ups, can now be redeployed into business growth and innovation.
    • Customer access to Saint-Gobain products – The approach enabled products from Saint-Gobain’s facility to be approved for use at a time when the pandemic was severely restricting access to audits. This supported delivery of product from many customers who wouldn’t otherwise have got access to an audit.
    • Better ‘trust’ with customers based on the quality of audit reports and the follow up process – The RX-360 provides a robust methodology for the management of audit programs, and any follow-up that may be required, in line with CAPA plans – something many customers are not able to manage as well.
    • Saint-Gobain was able to be proactive and manage the situation with an efficient approach to audit processes – offering a better overall service to its customers.

Lessons learned

Saint-Gobain Life Sciences’ team tackled several pushbacks relating to the audit program:

Lack of awareness/communication – Despite multiple communications from industry, many end users within Saint-Gobain’s supply chain were unaware of the Joint Audit Program®, or sceptical of the joint audit approach – with some major biopharmaceutical companies initially refusing to take part. There was also a lack of information sharing between different parts of complex global biopharmaceutical companies; Saint-Gobain learned that it had a part to play helping the awareness across its customers’ enterprises.

There were also internal challenges from Saint-Gobain’s own marketing team, which perceived a potential loss of opportunity to showcase its new facilities and capabilities to companies’ auditors during on-site visits. In response, the Saint-Gobain audit team clarified that executive decision makers from the supply chain would not normally attend audits, invalidating this concern.

Saint-Gobain helped to solve both of these communications issues by sharing the materials produced by members of BioPhorum’s Joint Audit Program® workstream, in partnership with Rx-360.

The audit was fantastic. From the very first one we thought ‘Wow’ – our customers can rely on this. It gave me the confidence, as a head within our organization, to feel comfortable now with encouraging our customers to accept this.

Polly Hanff, Global Regulatory Affairs and Quality Director

Rx-360

Rx-360, non-profit, is an international pharmaceutical supply chain consortium formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain. The organization’s mission is to protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of its materials primarily through its working group and unique audit program.

Cell & Gene Therapy

Maximizing the impact of the many advanced therapies under development requires that the industry comes together to improve understanding of how to develop, control and manufacture these life changing therapies.

We connect strategic thinkers in drug development and contract manufacturing organizations with the aim of ensuring harmonization and alignment around issues such as potency assays, phase-appropriate guidance for critical quality attributes, operator safety, regulatory guidelines, and C&GT-specific validation issues, as well as working toward resolving the current challenges to commercializing C&GT products. Discover more and learn about the outputs here.

Development Group

The ever-increasing need to reduce product development lead times and the opportunities to exploit innovative technologies in development are two key industry themes that remain at the forefront of our work. The Phorum successfully connects process development organizations and provides a space where subject matter experts can work on issues such as quality by design and process characterization, cell line technologies, and molecule selection. Read some of the outputs and discover how you could benefit by getting involved.

Drug Substance

Accelerating improvement, exploiting opportunities offered by innovation, and identifying best practice approaches across all aspects of the manufacturing process – these are the essential objectives

Data and digital capabilities are at the core of many of these industry challenges. Work in BioPhorum Drug Substance is informed by BioPhorum Technology Strategy, which has summarized our industry’s market drivers and trends. Capacity, flexibility, sustainability and pace all feature as requirements to succeed in a rapidly changing environment.

Find out more about what our members are currently discussing and learn about some of the successful implementations of our output.

Fill Finish

Quality and demonstrating compliance are two priorities of BioPhorum Fill Finish. Representatives of the world’s top sterile filling operations come together to develop solutions to some of the most intractable technical and regulatory challenges.To address these challenges in drug product aseptic filling (‘fill’) and secondary packaging (‘finish’) operations, our community of industry experts is working relentlessly to continually improve the pharmaceutical quality system (PQS). Together they continue to strive towards developing and implementing safe, predictable, lean, and agile processes in drug product operations. Find out more about the Phorum output here. 

Information Technology

IT and digital advances are crucial in responding to the pharmaceutical industry’s challenges around speed, cost, quality, flexibility, and sustainability. Unlocking and realizing the value in the industry’s IT opportunities is the core mission of the IT Phorum. 

The digital manufacturing facility of the future needs to consider technology advances alongside organizational perspectives while maintaining foundational security requirements. All elements must be considered in the long term to deliver systemic change toward the digital factory vision. Our members collaborate in a format that stimulates and supports industry innovation and implementation. 

Regulatory-CMC

BioPhorum Regulatory CMC is affording professionals the opportunity to shape their own collaboration program focused on challenges and opportunities across strategy, science, operations, submissions and compliance. Following a discovery program of work with Heads of Regulatory CMC, in which we identified some key topics of collaboration, we are giving you the opportunity to participate and help us to shape the final collaboration program. This will focus on, filing and review, interactions with Health Authorities, and harmonization. Our mission is not just to discuss, but to deliver applicable outputs and publications that will have an impact – learn more about how you can get involved.

Supply Chain to Patient

The pharmaceutical outbound supply chain was built on a blockbuster model and doesn’t fit the needs of the changing pipeline and new modalities currently being developed. The geopolitical challenges of recent years have shown that the outbound supply chain needs to evolve to become more agile, and resilient, and address a more expectant end-user bying on patient-centricity. Industry collaboration can accelerate improvements and transform performance in a way not possible when working independently. This Phorum is founded on the belief that learning from each other and challenging current thinking to re-imagine the supply chain can reduce costs and increase efficiency.

Supply Partner

BioPhorum SP members want the inbound supply chain for the biomanufacturing industry to be recognized as one of the best-understood and managed global supply chains. They intend to be not only a trusted advisory group but also the engine that drives change for the industry. Working together, we aim to achieve supply chain transformation that provides:

  • an enhanced robustness and resilience
  • accelerated capability and capacity to effect technology adoption
  • reduced cost of quality, and
  • industry-wide alignment on operational implementation

There’s an extensive list of Phorum successes and tangible benefits that have been delivered to define industry best practise.

Sustainability

The BioPhorum Sustainability program is jointly designed, governed, and delivered by a membership drawn from licence holders, contract manufacturers, major suppliers and niche suppliers. This dynamic partnership means that we can quickly focus on the areas that have the greatest industry impact, and we can leverage learning from each other and other sectors – the chemical industry and the built environment for example.

BioPhorum’s unique ability to build a strong coalition for change for an entire industry is now being applied to the greatest challenge of our generation. Driven by evident industry needs, Phorum members are working to develop agreed industry benchmarks, establish the ROI of sustainability investments and to increase the efficacy of implementation of members’ sustainability strategies.

Technology Strategy

With a mission to define strategies to accelerate technology transformation and support the adoption of innovative technologies, BioPhorum Technology Strategy evolved from BioPhorum Technology Roadmapping, strives to realize the technology roadmap vision 2.0.

This is being achieved through a multi-stakeholder team of member companies with collective capability and influence who are committed to driving forth industry goals associated with: Speed to market, Quality, Value, Agility and On-Demand Supply and Sustainability.

Best practices for demonstrating comparability for clinical cell-based therapies.

With the increased number of clinical trials using advanced novel cell-based therapies, much of the regulatory and industry guidance needs... read more

How to predict, optimize and analyze high-concentration biologic therapeutic formulations

Developing high-dose biologic drugs for subcutaneous injection often requires high-concentration formulations. It also needs to optimize... read more

A media fingerprinting toolbox that comes with a host of benefits

Cell culture media raw materials can contain many chemical substances, each with its own properties. While simple substances can be... read more

Why 100% visual inspection does not mean 100% defect detection

There is a common misunderstanding that 100% visual inspection (VI) of biopharmaceutical products should mean 100% detection of defects.... read more

How to bridge the data integration gap between sponsors and contract organizations

Bringing BioPhorum’s unique perspective to continuous manufacturing in biologics

Continuous manufacturing (CM) has been a goal for the pharmaceutical industry for several years. While small molecule drug substances and... read more

Supply Chain to Patient has launched!

Have your outbound supply chain costs increased? Do you want to leverage data and digital technologies more effectively to reduce... read more

Electronic data exchange – the foundation for an efficient, resilient inbound supply chain

The COVID-19 pandemic, geopolitical unrest, and military action across the world have fundamentally disrupted the assumption and practice... read more

How are you improving your environmental sustainability performance?

Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health.... read more

Adding value for analytical instrument partners

Analytical instrument vendors have been integral to developing and publishing our technology roadmaps and developing product... read more

Introducing MediPhorum

The medical technology (MedTech) industry is a critical and complex sector. As highlighted during the Covid-19 pandemic, the MedTech industry provides a wide array of products and technologies that are vital to the safe and effective provision of care to many. Also, as seen over recent years, there is often the requirement for flexibility in supply, rapid development, and the introduction of new products to keep pace with global public health demands.

Advanced Wound Care and Wound Management

Advanced wound care (AWC) is the medical treatment for wounds that have not healed properly using conventional wound care products such as gauze, bandages, plasters, and wadding.

AWC involves treating chronic or complex wounds using products that are not as easily obtained over the counter. AWC can be divided into three main categories: wound healing, infection prevention, and restoration.

Drug Delivery

Drug delivery products are therapeutic and diagnostic products combining drugs, devices, and/or biological products, which enable safer and more efficient treatment due to careful and precise drug targeting, local administration, and tailored treatment.

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more
BioPhorum Deliverables Report
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, position papers, guidance documents, assessment tools, industry user requirements, study results, and roadmaps produced in the last twelve months.
BioPhorum Downloads
Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.
Case Studies
Welcome to the BioPhorum case studies page, where you can learn how our clients have used our service to discover innovative solutions and save money. Here you can read real-life stories of how various organizations have used our unique data-driven approach to streamline their processes and make the most of their resources. Whether you're looking for inspiration or want to learn more about the potential benefits of our service, you'll find it here.
Webinars and podcasts
Welcome to BioPhorum Connect, the podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, this podcast brings you the insights and perspectives of experts from around the world. We'll discuss all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. So, join us on our journey as we explore the world of biopharmaceuticals and learn from the perspectives of those at the forefront of the industry.